Skip to main content

Crohn's Disease News

Research Highlights
09/18/2025
Jessica Garlewicz
Ustekinumab may offer a more durable and effective approach in managing this challenging patient population, new research shows.
Ustekinumab may offer a more durable and effective approach in managing this challenging patient population, new research shows.
Ustekinumab may offer a more...
09/18/2025
Advances in Inflammatory Bowel Disease Network
Research Highlights
09/04/2025
Rebecca Mashaw
Patients with fistulizing Crohn’s disease achieved higher rates of fistula resolution and clinical response with upadacitinib versus placebo.
Patients with fistulizing Crohn’s disease achieved higher rates of fistula resolution and clinical response with upadacitinib versus placebo.
Patients with fistulizing...
09/04/2025
Advances in Inflammatory Bowel Disease Network
Research Highlights
09/04/2025
Jessica Garlewicz
The study highlights a diagnostic blind spot in pediatric CD management and supports adding baseline pelvic MRI to initial workup, even in the absence of perianal symptoms.
The study highlights a diagnostic blind spot in pediatric CD management and supports adding baseline pelvic MRI to initial workup, even in the absence of perianal symptoms.
The study highlights a...
09/04/2025
Advances in Inflammatory Bowel Disease Network
Research Highlights
09/04/2025
Jessica Garlewicz
Study findings highlight mirikizumab as a therapeutic option that delivers not only symptom relief but also sustained improvements in quality of life and functional outcomes for patients with moderate to severe CD.
Study findings highlight mirikizumab as a therapeutic option that delivers not only symptom relief but also sustained improvements in quality of life and functional outcomes for patients with moderate to severe CD.
Study findings highlight...
09/04/2025
Advances in Inflammatory Bowel Disease Network
Research Highlights
09/04/2025
Jessica Garlewicz
The study met all primary and multiplicity-controlled secondary endpoints, including clinical and endoscopic outcomes through 48 weeks.
The study met all primary and multiplicity-controlled secondary endpoints, including clinical and endoscopic outcomes through 48 weeks.
The study met all primary and...
09/04/2025
Advances in Inflammatory Bowel Disease Network
News
08/28/2025
Rebecca Mashaw
A multicenter study confirms the accuracy and reliability of a simplified ultrasound score for assessing Crohn’s disease activity.
A multicenter study confirms the accuracy and reliability of a simplified ultrasound score for assessing Crohn’s disease activity.
A multicenter study confirms the...
08/28/2025
Advances in Inflammatory Bowel Disease Network
Research Highlights
08/21/2025
Rebecca Mashaw
Risankizumab demonstrates sustained clinical benefit and favorable safety in Crohn’s disease, including among ustekinumab-experienced patients.
Risankizumab demonstrates sustained clinical benefit and favorable safety in Crohn’s disease, including among ustekinumab-experienced patients.
Risankizumab demonstrates...
08/21/2025
Advances in Inflammatory Bowel Disease Network
News
07/29/2025
Jessica Garlewicz
Further studies are warranted to explore the underlying mechanisms and to refine screening strategies based on individualized risk.
Further studies are warranted to explore the underlying mechanisms and to refine screening strategies based on individualized risk.
Further studies are warranted to...
07/29/2025
Gastroenterology
Research Highlights
07/24/2025
Rebecca Mashaw
In a meta-analysis of 14 randomized clinical trials, Janus kinase inhibitors and other advanced therapies demonstrated significantly higher efficacy in colonic compared to ileal Crohn’s disease.
In a meta-analysis of 14 randomized clinical trials, Janus kinase inhibitors and other advanced therapies demonstrated significantly higher efficacy in colonic compared to ileal Crohn’s disease.
In a meta-analysis of 14...
07/24/2025
Advances in Inflammatory Bowel Disease Network
News
07/24/2025
Rebecca Mashaw
In both trials, guselkumab significantly surpassed placebo for primary composite endpoints of clinical response at week 12 followed by either clinical remission or endoscopic response at week 48.
In both trials, guselkumab significantly surpassed placebo for primary composite endpoints of clinical response at week 12 followed by either clinical remission or endoscopic response at week 48.
In both trials, guselkumab...
07/24/2025
Advances in Inflammatory Bowel Disease Network